Supernus Pharmaceuticals shares underperformed the S&P 500 on August 6, 2025, and belongs to the Generic Drugs industry.
2 reports, 2 independent
Updated Aug 6
Gone quiet
Reached 2 outlets in its first 24 hours
- Reports
- 2
- Developments
- 2
- Repetition
- 0%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Supernus Pharmaceuticals shares underperformed the S&P 500 on August 6, 2025, and belongs to the Generic Drugs industry.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.Supernus Pharmaceuticals shares underperformed the S&P 500 on August 6, 2025.1 source
Market fluctuations impacted investor sentiment for Supernus and IREN on August 6, 2025.1 source
Keep exploring
The entities involved
-
Supernus Pharmaceuticals (United States)
company in Rockville, United States
Nothing else this week.
Coverage
Newest first; wire copies grouped- ZacksSupernus Pharmaceuticals (SUPN) Surpasses Q2 Earnings and Revenue Estimates Supernus Pharmaceuticals (SUPN) came out with quarterly earnings of $0.91 per share, beating the Zacks Consensus Estimate o
- Simply Wall St.3 Stocks Estimated To Be Trading At Up To 49.3% Below Intrinsic Value In recent weeks, the U.S. stock market has experienced fluctuations as concerns about tariffs and economic indicators have impact